Key result
Surgery and adjuvant chemotherapy yield 3-year disease-free survival in rare cystic primary hepatic angiosarcoma.
Case Report (n=1)
No
This case report highlights a rare cystic presentation of primary hepatic angiosarcoma, which typically presents as a solid hypervascular tumor.
Single-case success with resection plus chemotherapy in cystic hepatic angiosarcoma warrants caution; hypothesis-generating and requires validation in larger cohorts.
Primary hepatic angiosarcoma is a rare malignancy arising from the endothelial cells. They account for 1% of all primary liver tumors. They are aggressive tumors and patients usually present with distant metastasis. Surgical resection is the mainstay of treatment, however recurrences are common. The overall survival of patient with hepatic angiosarcoma is only five months without any treatment. Addition of adjuvant chemotherapy with surgery seems to prolong the overall and disease-free survival. Their diagnostic dilemma is due to the fact of non-specific imaging findings mimicking other hypervascular liver tumors. Angiosarcomas are solid tumors arising from the endothelial cells. Cystic type of angiosarcomas are rare and those arising from the liver have not been reported. We are presenting a case report on a cystic primary hepatic angiosarcoma.
No takes yet. Share an insight, caveat, or question.
Chand et al. (2023) conducted a case report in Primary hepatic angiosarcoma (n=1). Surgical resection and adjuvant chemotherapy was evaluated on Clinical outcome. A 65-year-old female with a rare cystic primary hepatic angiosarcoma was successfully treated with surgical resection and adjuvant chemotherapy, remaining disease-free for three years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: